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Nathália Moreno Cury,1,2 Tobias Mühlethaler,3 Angelo Brunelli Albertoni Laranjeira,1
Rafael Renatino Canevarolo,1 Priscila Pini Zenatti,1 Daniel Lucena-Agell,4 Isabel Barasoain,4 Chunhua Song,5
Dongxiao Sun,5 Sinisa Dovat,5 Rosendo Augusto Yunes,6 Andrea Enrico Prota,3 Michel Olivier Steinmetz,3,7
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Molecular, Centro Infantil
Boldrini, Rua Dr. Gabriel
Porto 1270, Campinas
13083-210, BrazilSUMMARY
Tubulin is one of the best validated anti-cancer targets, but most anti-tubulin agents have unfavorable
therapeutic indexes. Here, we characterized the tubulin-binding activity, themechanismof action, and
the in vivo anti-leukemia efficacy of three 3,4,5-trimethoxy-N-acylhydrazones. We show that all com-
pounds target the colchicine-binding site of tubulin and that none is a substrate of ABC transporters.
The crystal structure of the tubulin-bound N-(10-naphthyl)-3,4,5-trimethoxybenzohydrazide (12) re-
vealed steric hindrance on the T7 loop movement of b-tubulin, thereby rendering tubulin assembly
incompetent. Using dose escalation and short-term repeated dose studies, we further report that
this compound class is well tolerated to >100 mg/kg in mice. We finally observed that intraperitone-
ally administered compound 12 significantly prolonged the overall survival of mice transplanted with
both sensitive and multidrug-resistant acute lymphoblastic leukemia (ALL) cells. Taken together, this
work describes promising colchicine-site-targeting tubulin inhibitors featuring favorable therapeutic
effects against ALL and multidrug-resistant cells.2Graduate Program in
Genetics and Molecular
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Despite the success already achieved in the treatment of children with acute lymphoblastic leukemia (ALL),
relapse still occurs in around 20% of patients (Steinherz et al., 1996; Stock et al., 2013). The overall survival
rate for relapsed childhood ALL is approximately 40%–60% despite intensive chemotherapy and allogeneic
stem cell transplantation (Oskarsson et al., 2015; Roy et al., 2005), highlighting the need for new drugs or
new drug formulations. Recent clinical trials in adults (reviewed in Soosay Raj et al., 2013) and children (Shah
et al., 2016) with relapsed or refractory ALL have shown promising results with the use of liposomal vincris-
tine. Vincristine has been in clinical use for decades and is one of the main components of every ALL pro-
tocol. Liposomal vincristine allowed the use of higher andmore frequent doses of this anti-tubulin agent by
circumventing its neurotoxic effects, which are likely caused by perturbations of microtubule functions that
are essential for axonal transport in neurons (Shah et al., 2016; Soosay Raj et al., 2013).
Tubulin is one of the best validated targets for cancer therapy. There are dozens of new anti-tubulin agents
in clinical or late preclinical development, pursuing better therapeutic indexes, i.e., a better trade-off be-
tween efficacy and toxicity (Field et al., 2015; Liu et al., 2014; Wood et al., 2001). In this context, our group
has designed and tested a series of 3,4,5-trimethoxy-N-acylhydrazones some of which exhibited strong
anti-microtubule and anti-leukemia activities, in vitro and in vivo, while showing modest toxicity toward
normal proliferating T cells (Salum et al., 2015). In this study, we highlight the biochemical and biological
properties of three 3,4,5-trimethoxy-N-acylhydrazones: compounds 7, 12, and 21, which showed the best
in vitro anti-leukemic effects in our previous study (Salum et al., 2015).
RESULTS
Compounds 7, 12, and 21 Bind to the Colchicine-Binding Site of Tubulin and Inhibit
Microtubule Assembly
Our previously reported computational docking efforts propose that N-acylhydrazones could adopt an
appropriate stereochemistry in the colchicine-binding site of tubulin (Salum et al., 2015). To test theiScience 21, 95–109, November 22, 2019 ª 2019 The Authors.
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Figure 1. Compounds 7, 12, and 21 Are Colchicine-Binding Site Tubulin Inhibitors
(A) Derivatives from N-acylhydrazones with the best in vitro anti-leukemic effects in Salum et al. (2015).
(B) Displacement of MTC from the colchicine-binding site by N-acylhydrazones. Fluorescence intensity of MTC bound to
tubulin after addition of 10 mM compounds 7, 12, and 21. Each curve represents the mean of three independent
experiments. See also Figure S2.
(C) Inhibition of tubulin assembly by compounds 7, 12, 21, and podophyllotoxin after 85 min of incubation. Absorbance
spectra of 25 mM tubulin in the presence of different concentrations (0.5–20 mM) of the three compounds studied or DMSO
(vehicle) was monitored over time by turbidity.
See also Figure S3.interaction of compounds 7, 12, and 21 (Figure 1A) with tubulin, we assessed the UV absorbance spectrum
of these compounds (Figure S1) followed by their ability to displace 2-methoxy-5-(20,30,40-trimethoxy)-2,4,6-
cycloheptatrien-1-one (MTC), a reversible tubulin ligand targeting the colchicine-binding site (Fitzgerald,
1976).
Compounds 7, 12, and 21 were capable of displacing the MTC probe, confirming their binding to the
colchicine pocket of tubulin (Figure 1B). Calculation of binding constants (Figure S2) revealed that com-
pound 21 binds tubulin with a 10 times higher affinity (binding constant of 5.03 107 M1) than compounds
7 (3.33 106 M1) and 12 (1.263 106 M1). For comparison, podophyllotoxin’s binding constant for tubulin,
in the same assay, was reported to be 1.85 3 107 M1(Antúnez-Mojica et al., 2016).96 iScience 21, 95–109, November 22, 2019
In the tubulin polymerization assay, which included podophyllotoxin as a positive control, all three com-
pounds were effective in inhibiting tubulin polymerization (Figure 1C). Inhibition of tubulin assembly by
these compounds over time is shown in Figure S3. We further investigated the effects of these compounds
in cellular tubulin depolymerization assays using the A-549 cell line. Microtubule network depolymerization
occurred at 200 nM for compounds 12 and 21, at 300 nM for compound 7, and at 100 nM for colchicine,
which was included as positive control (Figure 2A). Compound 21 was slightly more potent than the other
two compounds, because cells could be seen arrested in prometaphase and DNA was arranged in a ball of
condensed chromosomes with no microtubules, which is a type IV spindle. On the other hand, in mitotic
spindles seen in cells treated with compounds 7 and 12 the chromosomes were arranged in a ball enclosing
several star-shaped aggregates of microtubules characteristic of type III spindles (Jordan et al., 1992). In all
cases, mitotic arrest was accompanied by net microtubule depolymerization (Figure 2A).
Although compounds 7 and 12 had similar effects in the MTC displacement and tubulin depolymerization
assays, compound 12 was slightly more potent than compound 7 in promoting cellular microtubule depo-
lymerization (Figure 2A), suggesting that compound 12may have a better cellular bioavailability. Thus, the
next step was to investigate the cellular uptake of compounds 7, 12, and 21, after 30 min, 6 h, and 12 h of
incubation with each compound at a concentration (100 nM) that is close to their IC50 in cytotoxic assays. As
expected, mass spectrometric analyses of total cellular extracts showed a significant lower cellular uptake
of compound 7. Compound 12 had higher uptake after 30 min of treatment. However, its level decreased
after 6 and 12 h, whereas the amount of compound 21 increased with time (Figure 2B). Whether compound
12 is subjected to cellular metabolization remains to be investigated.
Compounds 7, 12, and 21 Are Not Substrates of ATP-Binding Cassette Transporters
Overexpression of ATP-binding cassette (ABC) transporters is involved in the cellular resistance to vinca alka-
loids and anti-cancer drugs in general, constituting one of the main causes of failure in cancer therapy (El-
Awady et al., 2017). To evaluate if compounds 7,12, and 21 were substrates of ABC transporter proteins,
cell viability assays were performed using four pairs of cell lines, each pair including a parental sensitive
cell line and its resistant derivative, known to overexpress ABC transporters. All resistant cells displayed a
typical multidrug resistance (MDR) phenotype, as evaluated by the calcein exclusion assay (Figure S4). Com-
pounds 7,12, and 21 showed similar IC50 values (Table 1) and cell-cycle arrest potency (Figure S5) for both
sensitive and resistant cell lines, indicating that these compounds are not good substrates of ABC transporter
proteins, which was not the case for colchicine, vinblastine, and vincristine. However, a modest 4- to 9-fold
increased resistance to the acylhydrazone compounds was observed for the colchicine-resistant mouse 3T3
embryonic fibroblastoid cell line. Considering the three pair of neoplastic cell lines, compound 12 showed
the lowest IC50 for all six cell lines, followed by compounds 21 and 7, respectively (Table 1).
Cell-Cycle Arrest, DNA Damage, and Apoptosis Caused by Acylhydrazone Compounds
We choose compound 12, which presented the best in vitro cytotoxic results, as our leading compound for
further mechanistic investigations. Increased in vitro proliferation of primary ALL cells was found to corre-
late with increased sensitivity to some chemotherapeutic drugs, including vincristine (Kaaijk et al., 2003). As
shown in Figure 3, we found no correlation (p = 0.1821) between the doubling time and in vitro resistance
(IC50) to compound 12 on a series of different precursor B cell ALL and T cell ALL cell lines (Table S1). To
investigate how compound 12 leads to cell death, the pre-B ALL leukemia cell line RS4;11 was treated with
compound 12 for 18 h and then labeled with bromodeoxyuridine (BrdU) and stained with antibodies
against H2AX and PARP. Treatment with compound 12 resulted in a population of cells with DNA content
in between G1 and G2, suggesting the occurrence of unequal division (Figure 4). DNA damage (H2AX) and
apoptosis (PARP) occurred both at the G1 and G2 phases of the cell cycle. These results suggest that cells
treated with compound 12 face cell death both as a consequence of mitotic arrest (in G2/M) and after un-
equal division; however, we cannot exclude the possibility of mitotic slippage followed by post-slippage
cell death. As unequal division could lead to the continuous cycling of some genomically unstable cells,
and the risk of secondary tumors, we investigated the generation of micronuclei. As shown in Table 2micro-
nuclei induction by compound 12 was comparable to that by colchicine and significantly lower than that by
vincristine.
Crystal Structure of the Tubulin Compound 12 Complex
To elucidate the tubulin-binding mode of compound 12, we solved its structure in complex with tubulin by
X-ray crystallography. To obtain crystals of tubulin, we complexed two a/b-tubulin heterodimers fromiScience 21, 95–109, November 22, 2019 97
Figure 2. Effects of Compounds 7, 12, and 21 on Microtubule Cytoskeleton and Their Cellular Uptake
(A) Effects of compounds 7, 12, and 21 on the cellular microtubule network of A-549 cells. A-549 cells were incubated for
20 h with DMSO (control, Ctr), 300 nM of 7, 200 nM of 12, 200 nM of 21, or 100 nM of colchicine. Anti-a-tubulin antibodies
and Hoechst 33342 were used to stain microtubules (green) and DNA (blue), respectively. Mitotic spindles from the same
preparation are shown in the right corner of each picture.
(B) Amount of compounds 7, 12, and 21 in total cellular lysates of CEM leukemia cells after 0.5, 6, or 12 h of treatment with
100 nM of the corresponding compound. The amount of each compound was normalized by the amount of protein from
the same sample. Each bar represents the mean G SD of three biological replicates. Data were analyzed by the two-way
ANOVA followed by Bonferroni’s post-test for mean comparisons (*p < 0.05; **p < 0.01; ***p < 0.001).
98 iScience 21, 95–109, November 22, 2019
Compounds versus Cell
Lines
7 12 21 Colchicine Vinblastine Vincristine
A2780 144 G 6 48 G 1 82 G 14 23 G 5 0.5 G 0.1 3 G 0.4
A2780/AD 101 G 11.1 20.6 G 2.0 55.9 G 1.4 270 G 49 29 G 5 457 G 131
Ratioa 0.7 0.4 0.7 11.7 57.3 154.6
KB 103 G 1.3 19.7 G 5.6 43.2 G 11 18.6 G 0.7 0.23 0.7
KB/VB 107 G 12.1 20.3 G 2.4 46.9 G 10 724 G 228 85.9 G 3.3 1130 G 100
Ratio 1.04 1.03 1.09 38.9 374.3 1608
CEM 116 G 27.6 31.4 G 8 54 G 0.7 14.5 G 0.3 0.6 0.7 G 0.2
CEM/VCR 122 G 25 32 G 11 50 G 6 281 G 5 128 G 3 1700 G 131
Ratio 1.05 1.02 0.93 19.42 213.65 2322.52
NIH3T3 65.7 G 4.4 13.2 G 4.3 109 G 15 30 G 3.5 1.02 G 0.02 2.8 G 0.7
NIH-MDR-G185 268 G 50 95.8 G 22 984 G 302 783 G 64.7 33.2 G 0.95 898 G 111
Ratio 4.08 7.25 9.02 26.1 32.5 320.7
Table 1. Cytotoxicity Data (IC50 G SD, nM) for Compounds 7, 12, 21, Colchicine, Vinblastine, and Vincristine against Human Neoplastic Cell
Lines
Cytotoxicity results are expressed as IC50 values, the compound concentrations producing 50% cell growth inhibition, and represent the meanG SD of three to
five independent experiments.
aDetermined by dividing the resistant cell line IC50 mean by the sensitive cell line IC50 mean.bovine brain with rat stathmin-like protein RB3 and chicken tubulin tyrosine ligase (the complex is denoted
T2R-TTL) (Prota et al., 2013a, 2013b). Subsequently, the compound was soaked into the T2R-TTL crystals,
and we were able to obtain X-ray diffraction data to 2.0 Å resolution (Table S2). We found that only the
colchicine site of the a1b1-tubulin was occupied with compound 12 (Figures 5A and S6). Superimposing
the T2R-TTL-compound 12 complex structure with the unliganded T2R-TTL structure (PDB: 4IHJ) showed
no major conformational changes upon ligand binding (root-mean-square deviation of 0.33 Å over 1,864
Ca-atoms).
The trimethoxyphenyl moiety of compound 12 fits in a predominantly hydrophobic pocket shaped by the side
chains of bTyr202, bCys241, bLeu242, bLeu248, bAla250, bLeu252, bLeu255, bAla316, bIle318, bAla354, and
bIle378 (Figure 5B). A second predominantly hydrophobic pocket is shaped by bAsn258, bMet259, bThr314,
bAla316, bLys352, aSer178, and aVal181 into which the naphthalene moiety of compound 12 is inserted. The
structurealso revealsawater-mediatedhydrogenbondbetween thenitrogenof theacylhydrazone linkerof com-
pound 12 and the backbone ofaThr179. A previous docking study (Salumet al., 2015) proposed three additional
hydrogen bonds. The first one is between the oxygen of the 30-methoxy of compound 12 and the side chain of
bCys241; our tubulin compound 12 crystal structure shows a distance between the two atoms of 3.9 Å, which
seems too long to allow for the permanent formation of a stable hydrogenbond. The other two hydrogen bonds
were predicted to be formed between the carbonyl group of compound 12 and themain chains of bAsp251 and
bLeu255.Our tubulin compound 12 crystal structure reveals distances of 3.6 and 4.3 Å, respectively, which are on
the higher side to establish stable hydrogen bonds. In conclusion, our analysis reveals that compound 12 estab-
lishes a single hydrogen bond with tubulin.
To elucidate the mode of action of compound 12 on tubulin, we superimposed several T2R-TTL crystal
structures. First, we compared the tubulin-compound 12 structure with the apo structure of tubulin
(PDB: 4IHJ). The major difference observed concerns the bT7 loop, which is flipped outward upon binding
of the ligand (Figure 5C). Second, we superimposed the binding mode of compound 12 onto the tubulin-
colchicine complex structure (PDB: 4O2B; Figure 5D). This analysis shows a large overlap of the two ligands
with only a minor shift of the aT5 loop due to the differing sizes of the two ligands. The bT7 loop is flipped
outward to nearly the same position for both compound 12 and colchicine. These observations indicate
that compound 12, like colchicine, causes steric hindrance on the bT7 loop movement, thus locking tubulin
in an assembly-incompetent conformation.iScience 21, 95–109, November 22, 2019 99
Figure 3. Cell Proliferation and Sensitivity to Compound 12 Do Not Correlate
Eleven ALL cell lines of precursor B cell ALL (Reh, RS4;11, 697, NALM-16, NALM-30) and T cell ALL (Jurkat, ALL-SIL, HPB-
ALL, TALL-1, P12-ICHIKAWA, MOLT-4) were analyzed regarding their doubling time and in vitro resistance (IC50 value;
see Table S1) to compound 12 at 48 h. Pearson’s r correlation test resulted in a no significant correlation (p = 0.1821 and
R2 = 0.1885).To determine the structural basis for the different tubulin-binding affinities by compounds 7, 12, and 21, we
modeled compounds 7 and 21 into the colchicine-binding site based on the crystal structure of the T2R-
TTL-compound 12 complex. These three acylhydrazones only differ in the size of their respective aromatic
moiety, which was nicely reflected in the minor rearrangements observed after energy minimization at the
end of the bH10-S9 loop and the start of bS9 strand. No perturbations of the bT7 loop or bH7 helix were
observed in themodels. To accommodate the bromine or methyl moieties of compounds 7 and 21, respec-
tively, the bH10-S9 loop and the start of bS9 strand shifted slightly away from the colchicine site (Figure S7).
Moreover, the 3,4,5-trimethoxy-acylhydrazone moieties minimally moved deeper into the binding pocket
by maintaining all binding interactions found in the structure of compound 12. Finally, the individual
changes from a naphthalene to a bromobenzene or a toluene moiety in compounds 7 and 21 only caused
a minimal conformational change in the aT5 loop. These observations suggest that both compounds lack-
ing the naphthalene moiety form more favorable interactions with the site, which agrees with their higher
binding affinities.Weight Loss Caused by Acylhydrazones 7, 12, and 21
We have previously shown that compound 12 is at least three orders of magnitude more toxic to leukemia
cells than to normal proliferating lymphocytes. In a single-dose acute toxicity study, compound 12 was safe
even at the maximum orally administered dose tested (1,000 mg/kg) (Salum et al., 2015). This time, we eval-
uated all three compounds in repeated dose and dose-escalating toxicity tests, which included also vincris-
tine and colchicine for comparisons. Mice receiving intraperitoneal (i.p.) injections ofN-acylhydrazones at a
dose of 1 or 10 mg/kg/day, for 2 weeks, showed no weight loss (Figure 6A). Similar results were seen in the
treatment with 0.15 mg/kg of vincristine or colchicine. However, mice treated with 1.5 mg/kg of vincristine
or colchicine died after 3 to 5 days (Figure 6A), confirming the narrow therapeutic indexes of these drugs.
In the dose-escalating experiment mice receiving daily escalating doses of vincristine and colchicine
showed abrupt weight loss followed death at a dose of 38.4 mg/kg. Increasing doses ofN-acylhydrazones,
on the other hand, were better tolerated. Compound 21 was the most toxic of the three N-acylhydrazones
tested. It caused weight loss and death at a dose of 256 mg/kg. Mice receiving compound 7 or 12 did not
show significant weight loss or any other clinical sign or behavioral alteration suggestive of intoxication,
even at 256 mg/kg (Figure 6B).In Vivo Anti-leukemia Effects of Compound 12
We have previously shown that compound 12 is able to inhibit the progression of patient-derived B cell
precursor ALL cells in immunocompromised mice at a weekly i.p. dose of 1 mg/kg (Salum et al., 2015).
Here we preliminarily evaluated different compound 12 treatment schemes on the survival of mice100 iScience 21, 95–109, November 22, 2019
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Figure 4. Multiparametric Flow Cytometry Analysis of Cell Cycle, Apoptosis, and DNA Damage in RS4;11 Cells
Treated with Compound 12
(A and B) Cells were treated with (A) DMSO (vehicle) 45 nM or (B) compound 12 (IC50 dose) for 18 h followed by labeling
with 10 mM BrdU for 45 min. The cells were then harvested and analyzed by immunofluorescent staining and multicolor
flow cytometric analysis using the BD FACSVerse Flow Cytometer. BrdU-positive cells are color-gated green, whereas
BrdU-negative cells at G1 phase, betweenG1 andG2 phase, and G2 phase of the cell cycle are colored red, light blue, and
dark blue, respectively.transplanted with the RS4;11 ALL cell line. Animals were treated for 4 weeks with DMSO (control); com-
pound 12 at 1 mg/kg, once a week, i.p.; compound 12 at 0.5 mg/kg, thrice a week, every other day, i.p.;
or compound 12 at 50 mg/kg, twice a week, orally. As shown in Figure 8, the dose of 1 mg/kg i.p. once
a week was not sufficient to prevent leukemia progression or improve survival of mice engrafted with
the RS4;11 leukemia cell line. On the other hand, compound 12 at a lower dose of 0.5 mg/kg, i.p., but given
thrice a week, had a profound impact on slowing the leukemia progression (Figure 7A) and as a conse-
quence on increasing animal survival (Figure 7B). Apparently, exposure of compound 12 to leukemia cells
for a longer time may be advantageous. Oral administration of compound 12 was the second best treat-
ment, however, at the expense of a much higher cumulative dose (100 mg/kg/week). These results suggest
that compound 12 has low oral bioavailability.
To validate the use of compound 12 against MDR cells in vivo, we use the pre-B cell ALL NALM6 or its MDR
counterpart, N6/ADR, which is characterized by P-glycoprotein overexpression (Treichel and Olken, 1992).
As expected, compound 12 showed similar IC50 values against both NALM6 and N6/ADR, which was not
the case for vincristine (Figure S8). Building on the better therapeutic profile of compound 12, mice were
treated with 10 mg/kg, i.p., every day, whereas vincristine was administrated i.p. once a week at a concen-
tration of 0.15 mg/kg (Szymanska et al., 2012). Both vincristine and compound 12 prolonged the overall sur-
vival of mice transplanted with NALM6, with vincristine being slightly more efficient than compound 12
(Figure 8A). However, only compound 12 was able to prolong the survival of mice transplanted with
N6/ADR (Figure 8B), corroborating with our hypothesis that compound 12 is more efficient than vincristine
against MDR leukemia.DISCUSSION
Vincristine is one of the backbone drugs of ALL treatment. It is a microtubule inhibitor whose major disad-
vantages are related to its limited bioavailability and high toxicity. Here, we report on three acylhydrazone
derivatives with microtubule-depolymerizing activities, which bind to the colchicine-binding site of tubulin,
distinctive from the vinca- and taxane-binding sites of the vinca alkaloids and taxanes currently used in
clinics.
As most other colchicine-binding site agents, and in contrast to vincristine and vinblastine, compounds
7,12, and 21 were demonstrated to be active against multidrug resistance (MDR) cells. Only the colchi-
cine-resistant mouse 3T3 embryonic fibroblastoid cell line NIH-MDR-G185 showed a modest resistance to
the acylhydrazone compounds; however, it was lower than the resistance observed to colchicine, vinblas-
tine, and vincristine. Of note, the NIH-MDR-G185 cell line was obtained through ectopic expression of
the MRD1 gene (Cardarelli et al., 1995), so the levels of P-glycoprotein expression may be much higher
than the levels observed in the patient-derived MDR cells. The ability to kill MDR cells may be
important in the context of relapsed ALL. Although overexpression of membrane-associated ABC
transporter was not associated to vincristine resistance at diagnosis (Holleman et al., 2004),
relapsed ALL was shown to express increased levels of multidrug resistance genes, including P-glycopro-
tein, lung resistance-related protein, and multidrug resistance-associated protein when compared with
diagnostic samples (Dhooge et al., 2002; Plasschaert et al., 2005; Terci Valera et al., 2004; van den Heu-
vel-Eibrink et al., 2000).
Among the three compounds tested, compound 12 is the one with the most favorable cytotoxic activity
(Table 1; Salum et al., 2015). Intriguingly, here we show that the tubulin-binding affinity of 12 is not superior
but slightly lower than that of compound 7 and 10 times lower than that of compound 21 in the MTC
displacement assay. Compound 7 showed a significantly lower cellular uptake than 12, therefore explain-
ing its lower cellular activity and suggesting that the bromobenzenemoiety present in compound 7 has the
lowest ability of crossing the cellular membrane compared with the toluene and naphthalene moieties102 iScience 21, 95–109, November 22, 2019





Vehicle (DMSO) 199 1 <0.0001 <0.0001
Colchicine IC50 174 26 – <0.0001
Vincristine IC50 99 101 <0.0001 –
12 IC50 163 37 0.1695 <0.0001
12 IC90 131 69 <0.0001 0.0017
Table 2. Micronuclei Formation Induced by Colchicine, Vincristine, and Compound 12
aFisher’s exact test. Colchicine IC50 = 13.5nM; vincristine IC50 = 1.1nM; compound 12 IC50 = 81.4nM; IC90 = 126.2nM.present in compounds 21 and 12, respectively. On the other hand, the cellular uptake of 21was even better
than that of 12. As compounds 12 and 21 share the same mode of action on tubulin (see below), how can
the better cytotoxic activity of 12 be explained, considering that 21 showed higher tubulin-binding affinity
and cellular uptake? a-tubulin and b-tubulin are encoded by multigene families, whose members may hold
differences in the amino acid composition of their colchicine-binding pocket. Compounds 12 and 21 may
have different affinities with each type of tubulin isotype (Kumbhar et al., 2016; Santoshi and Naik, 2014).
Leukemia cells express a mixture of different a- and b-tubulin isotypes (data not shown), which is probably
not matched by the calf brain tubulin composition used in the MTC displacement assay. Thus the in vitro
tubulin binding was not a perfect surrogate for the leukemia tubulin binding. Besides, the possibility exists
that the higher cellular uptake of 21 is due to off-target or unspecific cellular binding.
Concomitant analysis of cell cycle, DNA damage, and apoptosis revealed that compound 12 promoted
DNA damage and apoptosis not only in G2/M but also in G1. Death in G1 probably occurred after unequal
division of cells previously arrested in G2/M. Although unequal division could lead to secondary tumors, we
found micronuclei formation by compound 12 to be lower than that by vincristine, even at the dose of IC90.
Cells in S-phase were not sensitive to compound 12, which agrees with the fact that no correlation was
found between the proliferating index and compound 12’s IC50 values on a series of ALL cell lines.
The crystal structure of the tubulin-compound 12 complex confirmed the binding of compound 12 to the
colchicine-binding site of tubulin, which is located between the a- and b-tubulin subunits and shaped by
residues of loop T5 of a-tubulin and strands S8, S9, and S10, loop T7, and helices H7 and H8 of b-tubulin
(Ravelli et al., 2004). Free tubulin assumes a ‘‘curved’’ conformation. For tubulin to polymerize into micro-
tubules this curved conformation has to undergo a conformational change to reach the ‘‘straight’’ structural
form of tubulin. During this conformational change, the bT7 loop moves into the colchicine-binding site;
however, in the presence of a ligand, the bT7 loop is sterically hindered to assume the straight conforma-
tion. As a consequence, tubulin is locked in its curved conformation and becomes assembly incompetent
(Prota et al., 2014; Ravelli et al., 2004). Our structural analyses suggest that such a mechanism is indeed also
valid for compound 12. One peculiarity of compound 12 is that it forms only a single hydrogen bond with
tubulin, involving the nitrogen of the acylhydrazone linker of compound 12 and the backbone of a-tubulin
(residue aThr179). Other colchicine-binding site inhibitors so far characterized were shown to make at least
two hydrogen bonds, one of which is always with b-tubulin (Bueno et al., 2018; Gaspari et al., 2017; McNa-
mara et al., 2015; Prota et al., 2014; Wang et al., 2016; Zhou et al., 2016).
Energy-minimized models of both compounds 7 and 21 bound to the colchicine site revealed the same
mechanism of action, with no perturbations of the bT7 loop or bH7 helix. Three very small differences
were seen: (1) the 3,4,5-trimethoxy-acylhydrazonemoiety of 7 and 21moveminimally deeper into the bind-
ing pocket; (2) the bH10-S9 loop and the start of bS9 strand shift slightly away from the colchicine-binding
site to accommodate the bromine or methyl moieties of compounds 7 and 21, respectively; and (3) a min-
imal conformational change in the aT5 loop was recorded. No additional interactions of compounds 7 and
21 with tubulin were observed. These observations suggested that the higher affinities of both compounds
7 and 21 when compared with 12 do not derive from the formation of additional interactions, but rather
from the formation of more favorable interactions in the absence of the large naphthalene moiety, whichiScience 21, 95–109, November 22, 2019 103
Figure 5. X-Ray Analysis of the T2R-TTL-Compound 12 Complex
(A) Chemical structure of compound 12 and overall view of the a/b-tubulin heterodimer-compound 12 complex structure. Compound 12 (green spheres)
binds at the interface between a-tubulin (dark gray ribbon) and b-tubulin (light gray ribbon) in close proximity to the GTP (blue spheres)-binding site. See
also Figure S6 and Table S2.
(B) Close-up view of compound 12 (green sticks) and the surrounding binding pocket formed by a- and b-tubulin using the same color code as in (A). Carbon
atoms are depicted in gray for tubulin and green for compound 12; nitrogen and oxygen atoms are colored in blue and red, respectively. Interacting residues
are shown as sticks and are labeled; residues bTyr202, bAla316, bIle318, and bIle378 are omitted for clarity. Secondary structural elements of tubulin are
labeled in light blue.
(C) Same view and color code of the tubulin-compound 12 complex as in (B) with the apo T2R-TTL structure (purple; PDB: 4IHJ) superimposed.
(D) Same view and color code of the tubulin-compound 12 complex as in (B) with the structure of tubulin-colchicine (orange; PDB: 4O2B) superimposed.occupies a partially hydrophobic pocket in the crystal structure of compound 12. Themodeling data further
suggest that the difference in affinity between compounds 7 and 21 likely derives from the differing van der
Waals radii of their bromine and methyl moieties, respectively.
An attractive feature of these molecules is that they can be administered in higher doses than vincristine or
colchicine. As previously shown (Salum et al., 2015), we here confirm one of these compounds’ (compound
12) strong anti-leukemia activity as a single agent. Our exploratory in vivo toxicity test, measuring mice
weight loss, revealed that significantly higher doses of N-acylhydrazones can be administrated daily to
mice when compared with vincristine and colchicine, with no weight loss or clinical sign of toxicity. Com-
pound 21, however, was lethal at the highest dose tested in the escalating dose study. Whether this
increased toxicity is related to its higher neuronal (calf brain tubulin) tubulin-binding affinity or higher
cellular uptake remains to be investigated.
Remarkably, compound 12 prolonged the overall survival of mice transplanted with the RS4;11 ALL cell
line when given at a dose of only 0.5 mg/kg thrice a week; this dose given thrice a week was shown to
be better than 1 mg/kg given once a week. In addition, despite low oral bioavailability, compound 12
was shown to be effective against leukemia when administered by gavage. Pharmacokinetic studies
are warranted to improve the treatment schedule. Importantly, we validated the use of compound 12104 iScience 21, 95–109, November 22, 2019
Figure 6. Weight Loss of C57BL/6 Mice Treated with Compounds 7, 12, 21, Vincristine, and Colchicine
(A) Weight loss of C57BL/6 mice treated with escalating daily doses of N-acylhydrazones, vincristine, and colchicine.
Groups of two animals received daily i.p. injections of drugs at increasing doses of vincristine, colchicine, compound 7,
compound 12, or compound 21. The doses of vincristine and colchicine were 0.15, 0.3, 0.6, 1.2, 2.4, 4.8, 9.6, 19.2, and
38.4 mg/kg. The doses of 7, 12, and 21 were 1, 2, 4, 8, 16, 32, 64, 128, and 256 mg/kg.
(B) Weight loss of C57BL/6 mice treated with repeated daily doses of N-acylhydrazones, vincristine, and colchicine.
Groups of two animals received daily i.p. injections of drugs at two different dosages, during 13 consecutive days. In
control (Ctr), animals were injected with vehicle (2% DMSO, 10% Tween 20, 10% glycerol in PBS); d indicates that mouse
was dead on the next day. Dots are representative of a single animal. Data were analyzed by two-way ANOVA followed by
Bonferroni’s post-test for comparison of follow-up weights with the first weight for the corresponding animal (*p < 0.05;
**p < 0.01; ***p < 0.001).for the treatment of animals transplanted with a multidrug-resistant ALL cell line, although the
increased survival in this case was shorter than in mice transplanted with the RS4;11 cells, even when
higher doses of compound 12 were used (10 mg/kg every day). This probably reflects the higheriScience 21, 95–109, November 22, 2019 105
Figure 7. Anti-leukemia Effect of Compound 12 at Different Dose and Administration Routes
NOD/SCID mice were transplanted with RS4;11 ALL cells. After engraftment (>0.5% leukemia cells in peripheral blood
mononuclear cells), animals were randomly distributed into groups (n = 3) and treated for 4 weeks with vehicle or the
indicated schemes of compound 12.
(A) Leukemia progression as estimated by the percentage of leukemia cells in peripheral blood after engraftment. Note
that leukemia burden was measured every 7 days. Thus, the last measurement of leukemia in the peripheral blood does
not correspond to leukemia burden at death.
(B) Kaplan-Meyer survival curves of mice following the indicated schemes of compound 12 administration. Curves were
compared by the log rank test. For curves’ legend see (A). The indicated p values are for the comparison with the curve of
the control group.aggressiveness of NALM6/N6/ADR, and in any case, vincristine showed no efficacy against MDR cells
compared with compound 12.
In conclusion, we describe new promising colchicine-binding site tubulin inhibitors for the treatment of
ALL, featuring a favorable therapeutic index and activity against multidrug-resistant cells. In addition,
we provide a structural basis to understand how N-acylhydrazones destabilize microtubules, leading to
cell death.
Limitations of the Study
Although this study provided information regarding the cellular uptake of compounds 7, 12, and 21, sub-
sequent studies are necessary to investigate the differential metabolization of these compounds by the
cell, in particular compound 12, whose cellular concentration appeared to decrease at the longer time
points. This investigation can help design alternative compounds with increased half-life. In addition, in
this study we characterized the DNA damage and pro-apoptotic effects of 12 on cells at the different
phases of the cell cycle. Besides the expected effects of treatment (cells arrested in G2 and increased
numbers of apoptotic sub-G1 cells), we found a sub-population of cells having DNA content in between
G1 and G2, which we named ‘‘sub-G2’’ and interpreted as being cells that underwent unequal division
of their chromosomes. Cytogenetic analysis by fluorescence in situ hybridization of chromosomes would106 iScience 21, 95–109, November 22, 2019
Figure 8. Compound 12 Prolonged Survival of Mice Transplanted with Multidrug-Resistant ALL
(A and B) Kaplan-Meyer survival curves of mice transplanted with (A) NALM6 or the (B) multidrug-resistant N6/ADR ALL
cell lines, following treatment with compound 12 (10 mg/kg, i.p., every day), vincristine (0.15 mg/kg, i.p., weekly), or
vehicle. Treatment started on the fifth day after transplantation (dashed vertical line). Curves were compared by the log
rank test. The indicated p values are for comparison with the curve of the control group. See also Figure S8.be advisable to validate this finding. Regarding the in vivo experiments, it would be interesting to investi-
gate the effect of compound 12 against patient-derived ALL cells with multidrug-resistant phenotype. Last,
we noticed increased weight loss of animals receiving compound 12 orally, suggesting either harm by the
gavage process or gastrointestinal toxicity at a dose of 50 mg/kg twice a week.METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.DATA AND CODE AVAILABILITY
Atomic coordinates and structure factors for the T2RT-TTL-compound 12 complex have been deposited in
the RCSB Protein Data Bank (PDB) under accession number 6F7C.SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2019.10.003.iScience 21, 95–109, November 22, 2019 107
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Antúnez-Mojica, M., Rodrı́guez-Salarichs, J.,
Redondo-Horcajo, M., León, A., Barasoain, I.,
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Supplemental Figure S1. UV absorvance spectrum of compounds 7, 12 and 21 at 10 µM, 
Related to Figure 1A. Compounds were dissolved at a concentration of 5mM in DMSO, and 
then diluted to 10µM in 10mM Sodium Phosphate. Their UV absorbance spectra were measured 
in a Thermo Scientific EVOLUTION 201 UV spectrophotometer using blanks with the 




Supplemental Figure S2. Tubulin binding constants for compounds 7, 12, and 21 calculated 
based on MTC displacement curves, Related to Figure 1B. (A) Fluorescence emission spectra 
of MTC [2-methoxy-5-(2,3,4-trimethoxyphenyl)-2,4,6-cycloheptatrien-1-one] and tubulin in the 
presence of different concentrations (0.5 to 10 μM) of compound 7, 12 or 21. Bottom line is the 
fluorescence emission spectrum of MTC alone. Each curve represent the mean of three 
independent experiments. (B) Binding constant curves and values calculated by using the 
DosBox 0.73 software. 
 
Supplemental Figure S3. In vitro tubulin assembly inhibition by compounds 7, 12, 21, and 
podophyllotoxin, evaluated by turbidity measurment at a wavelength of 350 nm and 37 °C, 
Related to Figure 1C. Each curve represent the mean of three independent experiments. 
Absorbance spectra of 25 μM tubulin in glycerol-assembling buffer, GAB (3.4 M glycerol, 10 
mM sodium phosphate, 1 mM EGTA, 1 mM GTP, pH 6.5), in the presence of different 
concentrations (0.5 to 20 μM) of the ligand studied or 3% of DMSO (vehicle) was monitored 
along time by turbidity using a Varioskan Flash multimode microplate reader (Thermo 
Scientific) at a wavelength of 350 nm and 37°C. 
 
Supplemental Figure S4: Resistant cell lines expressing the Multiple Drug Resistance 
Phenotype, Related to Table 1. The four pairs of cells used in the cell growth inhibition assay, 
represented by a sensitive and a resistant cell line, were treated with DMSO, Calceín or Calceín 
+ Verapamil (a P-glycoprotein inhibitor) for 30 minutes and analyzed by flow cytometry. The 
calceín and verapamil doses were 1 uM and 25 uM respectively. 
 
Supplemental Figure S5. Compounds 7, 12 and 21 induce cell cycle arrest in G2/M, Related 
to Table 1. Cell cycle histograms of (A) A2780 (B) A2780/AD. Both cells were treated with 
DMSO (negative control), compounds 7, 12, 21, colchicine, vimblastine and vincristine. Cells 
were incubated for 20 h at concentrations ranging from 1 nM to 2.5 μM and submitted to cell 
cycle analysis with propidium iodide staining and flow citometry analysis. The lower ligand 















Supplemental Figure S6. Overall view of the T2R-TTL-compound 12 complex structure 
and electron-density map of compound 12 bound to tubulin in the T2R-TTL complex, 
Related to Figure 5. (A) Overall view of the T2R-TTL-compound 12 complex structure in 
ribbon representation. The - and -tubulin chains are colored in dark and light grey, 
respectively, TTL is in purple and RB3 is in dark green. The tubulin-bound compound 12 ligand 
is represented in green spheres. (B) Electron-density map of compound 12 bound to tubulin in 
the T2R-TTL complex. The SigmaA-weighted 2mFo - DFc (dark blue mesh) and mFo - DFc 
(light green mesh) omit maps are contoured at +0.9σ and +2.5σ, respectively. The map 














Supplemental Figure S7. Compounds 7 and 21 modeled into the crystal structure of 
compound 12, Related to Figure 5. Close-up view of compound 12 (green sticks), compound 7 
(magenta), and compound 21 (purple) and the surrounding binding pocket formed by α- and β-
tubulin represented as ribbons. Ribbons are depicted in grey for tubulin derived from the 
structure and magenta and purple for the models. Carbon atoms are shown in green for 
compound 12, magenta for compound 7 and purple for compound 21; nitrogen, oxygen and 
bromine atoms are colored in blue, red and brown, respectively. Secondary structural elements of 
tubulin are labeled in light blue. 
 
Supplemental Figure S8. Caracterization of sensitive NALM6 and Multidrug-Resistant 
N6/ADR cell lines, Related to Figure 8. (A) NALM6 and N6/ADR cells were treated with 
Calcein (red histogram) or Calcein + Verapamil (a P-glycoprotein inhibitor; blue histogram) for 
30 minutes and analyzed by flow cytometry. The calcein and verapamil doses were 1 uM and 25 
uM respectively. (B) Survival curves illustrating the cytotoxicity data for compound 12 and 
vincristine against NALM6 and N6/ADR cell lines after 48 hours of treatment. IC50 for 
compound 12 against NALM6 and N6/ADR were 88.5 nM and 85.8 nM respectively, while IC50 
for vincristine was 0.87 nM for NALM6 and 9 nM for N6/ADR.  
Supplemental Table S1. Proliferation index and Cytotoxicity Data (IC50, nM) for 
compound 12, against ALL Cell Lines, Related to Figure 3. 
ALL cell lines Doubling time IC50 #12 (nM) 
REH 1.6 92.6 
RS4;11 1.4 42.3 
697 1.0 62.5 
Nalm16 2.5 47.6 
Nalm30 3.2 43.9 
Jurkat 0.8 84.3 
SIL-ALL 1.4 42.3 
HPB-ALL 1.5 85.8 
TALL-1 0.9 89.2 
P12-ICHIKAWA 1.1 138.0 
Molt4 1.0 54.0 
 
Supplemental Table S2. X-ray diffraction data collection and refinement statistics of the 
T2R-TTL-compound 12 complex, Related to Figure 5. 
 T2R-TTL-compound 12 
Data collectiona  
Space group P212121 
Cell dimensions  
     a, b, c (Å) 104.5, 157.4, 180.8 
Resolution (Å) 59.5 – 2.0 (2.05 – 2.00) 
Rmeas (%) 10.9 (413.1) 
Rpim (%) 3.3 (118.0) 
CC1/2b 99.9 (25.4) 
I/σI 17.8 (0.7) 
Completeness (%) 99.8 (98.7) 
Redundancy 13.5 (13.2) 
Refinement  
Resolution (Å) 59.5 – 2.0 
No. unique reflections 199860 
Rwork/Rfree (%) 21.2 / 24.3 
Average B-factors (Å2)  
     Complex 63.8 
     Solvent 55.7 
     Ligand (chain B) 74.7 
  
Wilson B-factor 45.2 
Root mean square deviation from ideality  
     Bond length (Å) 0.006 
     Bond angles (°) 0.773 
Ramachandran statisticsc  
     Favored regions (%) 97.46 
     Allowed regions (%) 2.54 
     Outliers (%) 0.00 
a Highest shell statistics are in parentheses. b CC1/2= percentage of correlation between intensities from random half-
datasets(Karplus and Diederichs, 2012). c As defined by MolProbity (Davis et al., 2004). 
TRANSPARENT METHODS  
 
3,4,5-trimethoxy-acylhydrazones 
Compounds 7, 12, and 21 were synthesized as described before (Salum et al., 2015). 
Identity and purity were confirmed by mass spectrometry and nuclear magnetic resonance. For in 
vitro experiments, compounds were dissolved in dimethyl sulfoxide (DMSO) from Sigma-
Aldrich (St. Louis, MO, USA). DMSO concentration in the assay was ≤ 0.5%. For animal 
experiments, compound 7, 12, or 21 were dissolved in DMSO at 10 mg/mL. Then, a volume 
corresponding to 10 mice’s injection was mixed with 100 μL of Tween 20 and 880 μL of PBS, 
incubated at 37ºC for 5 min, and 100 μL were injected per animal. For UV absorbance spectra, 
the compounds were dissolved at a concentration of 5 mM in DMSO, and then diluted to 10uM 
in 10 mM sodium phosphate. Their UV absorbance spectra were measured in a Thermo 
Scientific EVOLUTION 201 UV spectrophotometer using blanks with the appropriate 
concentration of DMSO. 
 
Cell lines culture and viability assays 
We used five pairs of cells and their MDR derivates in this study: 1) The human ovarian 
cancer cell line A2780 and its MDR derivative, A2780/AD; 2) CCRF-CEM (CEM) and CEM-
vincristine-resistant (CEM/VCR (Haber et al., 1989)), which were a generous gift from Professor 
Maria Kavallaris (Children Cancer Institute, Australia), 3) KB-3-1 (KB) cell line derived from 
human epidermal carcinoma cells and its MDR mutant derivative KB-V1 resistant to vinblastine 
(KB/VB) (Shen et al., 1986), 4)  NIH3T3 cell line established from NIH Swiss mouse embryo 
cultures and its MDR NIH-MDR-G185 cell line, that is a clone of NIH3T3 cells transfected with 
the retroviral vector pHaMDR1/A (wild-type glycine at position 185), resistant to colchicine 
(Cardarelli et al., 1995), 5) B-ALL NALM6 cell line and its MDR derivate N6/ADR (ATCC® 
CRL-3274) also used in an in vivo assay. The human non small cell lung carcinoma A-549 cells 
(ATCC® CCL-185) as well as the adherent cells A2780, A2780/AD, KB, KB/VB, NIH3T3 and 
NIH-MDR-G185 used in this study were grown in DMEM supplemented with 10% fetal bovine 
serum, 2 mM L-glutamine, and 100 U/mL penicillin and 100 µg/mL streptomycin (Sigma-
Aldrich, Saint Louis, MO, USA). The acute lymphoblastic leukemia cell lines NALM6, 
N6/ADR, CEM, CEM/VCR, Nalm16, Nalm30, REH, SIL, RS4;11, HPB, 697, Molt4, P12-
Ichikawa, Tall-1 and Jurkat were cultured in RPMI-1640 (Cultilab, Campinas, SP, Brazil) 
supplemented with 10% fetal bovine serum (Cultilab), penicillin 100 IU/mL and 100 μg/mL 
streptomycin. Cells were maintained in a 5% CO2-humidified incubator at 37°C. RS4;11 B-cell 
ALL cell used in the in vivo study was kindly provided by Dr. Sheila A. Shurtleff (St Jude 
Children’s Research Hospital, Memphis, TN).  
Cell viability experiments were performed in 96-well micro-titer plates using the MTT 
reduction assay (0.5mg/ml final concentration, 4 hrs incubation) after 48 h of treatment. The 
formazan dye formed by the viable cells was dissolved by the addition of acid sodium dodecyl 
sulfate solution (10% SDS, 0.01 mol/L HCl). Following overnight incubation, absorbance was 
measured at 570 nm and 620 nm. Percentage of cell survival was calculated in relation to 
controls. IC50 values were calculated from dose-response curves using the GraphPad Prism 5 
(GraphPad Software, La Jolla, CA, USA) software. 
 
Immunofluorescence Analysis 
A-549 cells were plated (160,000 cells/mL) and cultured overnight in 24-well tissue 
culture plates containing 12 mm round coverslips. Next, cells were treated with different 
concentrations of the drugs or vehicle (DMSO) for 24 h. Cells were permeabilized with 0.5% 
Triton X100 and fixed with 3.7% formaldehyde, as previously described (de Ines et al., 1994). 
Then, cells were incubated with the anti-α-Tubulin monoclonal antibody, DM1A (Sigma-
Aldrich) for 1 hour and 30 minutes at 37°C , washed twice in PBS and incubated with FITC-
conjugated secondary goat anti-mouse polyvalent immunoglobulins antibody (Sigma-Aldrich) 
for 1 hour at 37°C. The coverslips were washed, and the nuclei of the remaining cells were 
labeled with 1 μg/mL of Hoechst 33342 for 30 min. Finally, samples were washed, examined 
and photographed using a Zeiss Axioplan epifluorescence microscope. The images were 
recorded with a Hamamatsu ORCA-FLASH 4.0 cooled CCD camera. 
 
Tubulin Polymerization Assay 
Polymerization of 25 μM calf brain tubulin maintained in glycerol-assembling buffer (3.4 
M glycerol, 10 mM sodium phosphate, 1 mM EGTA, 1 mM GTP, pH 6.5), and in the presence 
of different concentrations of the ligand studied or 3% of DMSO (vehicle) was monitored along 
time by turbidity using a Varioskan Flash multimode microplate reader (Thermo Scientific) at a 
wavelength of 350 nm and 37 °C. 
 
Ligand Binding to Tubulin 
The effect of different concentrations of compounds 7, 12 and 21 in the binding of 2-
methoxy-5-(2,3,4-trimethoxyphenyl)-2,4,6-cycloheptatrien-1-one (MTC) (Fitzgerald, 1976) to 
calf brain tubulin was verified as described previously (Andreu et al., 1998; Regina et al., 2007). 
Briefly, different concentrations (0.5 to 10 μM) of compound 7, 12 or 21 were added to 10 μM 
tubulin and 10 μM MTC in 10 mM sodium phosphate, 0.1 mM GTP buffer, pH 7.0. The 
incubation of 30 minutes for compounds 7 and 21 and one hour for compound 12, at room 
temperature, was followed by measurement of fluorescence emission spectra of MTC in the 
FluoroMax-2 equipment. Binding constants were calculated using the EQUIGRA 5 software 
(Díaz and Buey, 2007).  
 
Analysis of cellular uptake by HPLC-MS/MS 
Five million CEM (T-ALL) cells were treated with 100 nM of compounds 7, 12, or 21. After 0.5, 
6 or 12h. Cells were collected, washed 3x times with cold PBS, pelleted by centrifugation, 
ressuspended in 350 µL of PBS and sonicated for three cycles of 20 seconds in a Bioruptor 
equipment (Liege, Belgium). Total protein was measured using the BCA Protein Assay Kit 
(Thermo Fisher Scientific Waltham, MA) and compounds were quantified by mass spectrometry. 
Standard solutions at different concentrations were prepared by serial dilutions of each 
compound in methanol. Compound 21 (95 ng/mL) was used as internal standard for compound 
12 analysis, and compound 12 (100 ng/mL) was used as internal standard for compounds 7 and 
21 analyses. Calibration standards were prepared by mixing 20 µL of blank cell homogenate, 6 
µL of standard solution, 6 µL internal standard and 28 µL of methanol (to precipitate the 
proteins), to final standard concentrations from 1 ng/mL to 1000 ng/mL. Homogenates (20 µL) 
from drug treated cell samples were mixed with 6 µL of internal standard and 34 µL methanol. 
Samples were vortexed, followed by centrifugation at 4C for 10 min at 8765 g. The 
supernatants were analyzed using an ABSciex 4000 Q Trap mass spectrometry coupled with a 
Waters Acquity UPLC separation system. A 1.7 µm Acquity UPLC  BEH C18 analytical 
columm (2.1 x 100 mm, Waters, Ireland) was used and the gradient elution was conducted using 
a flow rate of 0.3 mL/min with the following conditions: Initiate in 10% mobile phase B 
(acetonitrile) and 90% solvent A (0.1 % formic acid in water), a linear gradient to 100% mobile 
phase B in 2 minutes, and keep the 100% mobile phase B for 2 minutes to flush the column. The 
autosampler was kept at 4°C, and the column temperature was maintained at 35°C. The ABSciex 
4000 Q Trap mass spectrometer was equipped with an electrospray ionization probe operated in 
positive mode. The decluster potential (DP) for compound 12, 21 and 7 was 77 V, 83 V and 78 V 
respectively; the entrance potential (EP) was 9 V, the collision energy (CE) for compound 12, 21 
and 7 was 27.6 V, 27.6 V and 31.8 V respectively; the collision cell exit potential (CXP) for 
compound 12, 21 and 7 was 14 V, 15.5 V and 14.6 V respectively. The curtain gas (CUR) was 
10 L/h, the collision gas (CAD) was 12 h/L. The ionSpray voltage was 5500 V, the temperature 
was 550C, the ion source gas 1 was 60 h/L and the ion source gas 2 was 50 h/L. The multiple 
reaction monitoring mode (MRM) was used to analyze and quantify the 3 compounds, with the 
transitions of m/z 365 > 195 for compound 12, 329 > 195 for compound 21 and 393 > 195 for 
compound 7. All peaks were integrated and quantified by ABSciex Multiquan 3.1 software. The 
standard curves were constructed by plotting the ratio of the peak area of the analyte to the peak 
area of internal standard versus analyte concentration. The amount of compounds obtained by 
mass spectrometry analysis was normalized by the amount of protein from the same sample. 
 
Cell Cycle Analysis 
For cell cycle analysis, 180,000 cells in 1 mL were incubated with different 
concentrations of the drugs for 20 h, then  fixed in 70% ethanol, washed with PBS, and incubated 
at 37°C for 15 min in 1 mL PI Buffer (0.1% Triton X-100, 0.2 mg/mL RNAse, and 20 μg/mL 
propidium iodide, in PBS). Ten thousand events were analyzed in a Coulter Epics XL flow 
cytometer. RS4;11 analysis of cell cycle and apoptosis was performed following the Apoptosis, 
DNA Damage and Cell Proliferation Kit protocol from BD Pharmingen™. 
 
Micronuclei formation  
1,5 x 106 Jurkat T-ALL cells in 5 mL were incubated with vehicle (DMSO), colchicine 
(IC50 dose= 13.5 nM), vincristine (IC50 dose= 1.1 nM) and compound 12 at the dose of IC50 (81.4 
nM) and IC90 (126.2 nM) for 24 h. Cells were harvested followed by Wright staining procedure 
for 3 minutes.  A total of 200 cells were counted for each treatment using the Olympus BX51 
microscope.  
 
In vivo weight loss using escalating and repeating doses of compounds 7, 12 and 21.  
C57BL/6 mice were acquired from the animal facility of the State University of 
Campinas. Animals were housed in individually ventilated cages, at 22 ± 1 ºC, under a 12-h 
light/12-h dark cycle, with food and tap water ad libitum. The numbers of animals, study design, 
and treatment of animals were reviewed, and approved by the Ethics Committee in Animal 
Experimentation of the State University of Campinas and registered under Protocol #3624-1. For 
the dose-escalating study, ten 7- to 8-weeks-old mice were randomly distributed in five groups 
(compounds 7, 12, 21, vincristine and colchicine) of two animals. Escalating doses of drugs, 2x-
fold daily increase, were given intraperitoneally (ip) for 9 consecutive days. For compounds 7, 
12 and 21 the doses used were 1, 2, 4, 8, 16, 32, 64, 128 and 256 mg/kg. For vincristine and 
colchicine the doses used were 0.15, 0.3, 0.6, 1.2, 2.4, 4.8, 9.6, 19.2, and 38.4 mg/kg. Control 
mice were administered the same volume of vehicle (2% DMSO in saline). Mice death, weight 
loss, intake of food and drink were registered during the 9 days. 
For the repeated-dose study, twenty-two C57BL/6 mice >10 weeks old were randomly 
divided in six groups and received daily ip injections of the test compounds for 13 consecutive 
days. Two different dosages were tested: 1 mg/kg and 10 mg/kg for compounds 7, 12, and 21; 
0.15 mg/kg and 1.5 mg/kg for vincristine and colchicine. Control group of animals received 
vehicle (2% of DMSO, 10% of Tween, 10% of glycerol and 78% of PBS). The location of the ip 
injection was alternating between lower left and lower right abdominal quadrants. Mice death 
and weight were registered until day fifteen.  
 
In vivo drug treatment of ALL xenografts mice transplanted with a human ALL 
Animal experiment using RS4;11 cell line was approved by the Ethics Committee in 
Animal Experimentation of the State University of Campinas and registered under Protocol 
#3624-1. Ten million RS4;11 cells were washed with PBS and injected in unconditioned 
NOD/SCID (NOD.CB17-Prkdcscid/J) mice (The Jackson Laboratory, Bar Harbor, ME) via the 
tail vein. Animals were monitored every 7 days for leukemia engraftment.(Lock et al., 2002) 
Briefly, blood was collected by retro-orbital bleeding into EDTA containing tubes, mononuclear 
cells were isolated by ficoll centrifugation and labeled with anti-human CD45-PE (clone HI30, 
BD Pharmingen,San Diego, CA or EXBIO, Prague, Czech Republic) and anti-mouse CD45-
FITC (clone 30F-11, BD Pharmingen) antibodies. The presence and quantity of leukemia cells 
was evaluated by flow cytometry in a FACSCanto II equipment (Becton Dickinson, Franklin 
Lakes, NJ). When human CD45(+) cells reached 0.5% of total CD45 peripheral blood cells in 
half of the animals, they were randomly distributed among the different treatment groups: 
placebo (saline solution), compound 12 (1 mg/kg, 1x per week, intraperitoneally), compound 12 
(0.5 mg/kg, 3x per week, every other day, intraperitoneally) or compound 12 (50 mg/kg, 2x per 
week, oral). Compound 12 was poorly dissolved when given at 50 mg/kg. Treatment lasted four 
weeks only. Every week, before the administration of saline or compound 12, weight was 
recorded and blood was collected to measure the percentage of leukemic cells (hCD45+ cells) by 
flow cytometry, as already described. Overall survival was measured from the date of 
inoculation to animal death.  
The animal experiment using NALM6 and N6/ADR cells were conducted under protocol 
number #46695 approved by the Institutional Animal Care and Use Committee at Penn State 
Hershey, Hershey, PA. NALM6 and N6/ADR cells (5x104) were injected via tail vein into 4-6-
week-old NRG, NOD-Rag1null IL2rgnull, NOD rag gamma mice (The Jackson Laboratory). 
Starting five days after cell injection, mice (n=5-6 per group) received vehicle (1% PVP, 4% 
DMSO, 95% PBS), compound 12 or vincristine daily via intraperitoneal at 10mg/kg/day until 
their death. Overall survival was measured from the date of inoculation to animal death. After 
death, animals were checked for splenomegaly to confirm the death from leukemia. When 
necessary, flow cytometry analysis of spleen cells using anti human CD19 and CD10 antibodies 
was performed. 
 
Crystallization, data collection and structure determination 
Crystals of T2R-TTL were grown as described by Prota et al. (A. E. Prota et al., 2013; 
Andrea E. Prota et al., 2013). Briefly, the T2R-TTL complex was crystallized by the vapor-
diffusion method at 20°C. Crystals grew over night in precipitant solution consisting of 5% PEG 
4K, 16% glycerol, 30 mM MgCl2, 30 mM CaCl2, 100 mM MES/Imidazole, pH 6.5. The crystals 
were soaked for 3 hours at 20°C in reservoir solutions containing 5 mM of compound 12, 10% 
PEG 4K and 16% glycerol, followed by a consecutive transfer to reservoir solutions containing 
20% glycerol before flash-cooling in liquid nitrogen. Native data were collected at 100K at 
beamline X06SA of the Swiss Light Source (Paul Scherrer Institut, Villigen, Switzerland). Data 
were processed and merged with XDS (Kabsch, 2010). The T2R-TTL-compound 12 structure 
was determined by the difference Fourier method using the phases of the T2R-TTL complex 
(PDB ID 5LXT) in the absence of ligands and solvent molecules as a starting point for 
refinement. The models were first fitted by several cycles of rigid body refinement followed by 
simulated annealing and restrained refinement in Phenix (Adams et al., 2010). The resulting 
models were further improved through iterative model rebuilding in Coot (Emsley and Cowtan, 
2004) and refinement in Phenix. The quality of the structures was assessed with MolProbity 
(Davis et al., 2004). Data collection and refinement statistics are given in Supplemental Table 
S1. Chains in the T2R-TTL complex were defined as follows: chain A, 1-tubulin; chain B, 1-
tubulin; chain C, 2-tubulin; chain D, 2-tubulin; chain E, RB3; chain F, TTL. Structure 
visualization, molecular editing and figure preparation were performed with the PyMOL 
molecular graphics system (The PyMOL Molecular Graphics System, Version 1.8.4.2. 
Schrödinger, LLC).  
 
Modeling 
To rationalize the observed structure/affinity relationship between the studied agents, 
both compound 7 and 21 were first modeled into the colchicine site using the binding pose of the 
3,4,5-trimethoxy-acylhydrazone moiety of compound 12 as a starting point and then minimized 
by using the MAB all atom force field in Moloc (Gerber and Muller, 1995). To accommodate the 
ligands, only the αT5- (173-182), the βT7- (245-251) and the βH10-S9-residues (343-352) were 
relaxed during energy minimization, while all remaining residues were kept fixed. 
Statistical analysis 
The statistical tests are mentioned in each figure legend. Statistical analyses were 
performed using the GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA) software. 
 
Data and Software Availability  
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